More than 150 representatives from patient organizations, industry, academia, and the world of regulation met in Warsaw...
More than 150 representatives from patient organizations, industry, academia and the world of regulation met in Warsaw today to plan the next stage of an ambitious European project aimed at increasing the involvement of patients in the development of new medicines.
At the heart of their discussions was the devising of a strategy to reach at least 100,000 European citizens with an interest in health. The idea is to equip them with information and tools to understand how the development process works – and perhaps motivate them to become more involved in it.
The workshop was held by the European Patients' Academy, known as EUPATI, funded by Innovative Medicines Initiative, a partnership of the European Commission with the European Federation of Pharmaceutical Industries and Associations (EFPIA).
The scene was set by Anna Zawada from Poland's Agency for Health Technology Assessment. Patient involvement is written into the agency's operating principles, she said. But in practice, it can be hard to find patients with sufficient expertise and confidence to fill the roles assigned to them.
Anna Zawada's introduction was followed by the first public presentation of EUPATI-sponsored research into public knowledge of and attitudes to medicines development across Europe.
Bella Starling from the University of Manchester and the UK NHS's Central Manchester University Hospitals revealed – perhaps predictably – low levels of knowledge of medicines development across Europe, including about how patients can contribute to the process. But there is also considerable public interest in the area, though accompanied by a lack of trust in the authorities and the industry in some countries.
The research evidence will underpin EUPATI as it develops its plans to communicate with the health-interested public. Those plans will be supplemented by suggestions made at the workshop – and by some of the more than 700 live Tweets coming in to the workshop at #eupati2014.
Top of the list of suggestions is the growing importance of social media as a way of reaching the public generally, especially the young and people with reduced levels of literacy. "We need to be open to the possibilities of technology, not fearful," said Nicola Bedlington from the European Patients' Forum.
The lynchpin of the plan to engage hundreds of thousands of Europeans will be EUPATI's new Internet Library. Project director Jan Geissler explained that this will come online towards the end of 2015, and will be available in seven European languages – English, French, Spanish, Italian, German, Polish and Russian.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.